OPEN END-TURBO-OPTIONSSCHEIN - KENVUE Share Price

Certificat

DE000HS0UNK0

Real-time BOERSE MUENCHEN 01:06:29 02/07/2024 am IST
0.1 EUR -16.67% Intraday chart for OPEN END-TURBO-OPTIONSSCHEIN - KENVUE
1 month-47.83%
3 months-73.33%
Date Price Change
02/24/02 0.1 -16.67%
28/24/28 0.12 -14.29%
27/24/27 0.14 -6.67%
26/24/26 0.15 -6.25%
25/24/25 0.16 -15.79%

Real-time BOERSE MUENCHEN

Last update July 02, 2024 at 01:06 am IST

More quotes

Static data

Product typeKnock-Out ohne Stop Loss
Buy / SellCALL
Underlying KENVUE INC.
Issuer HSBC
WKN HS0UNK
ISINDE000HS0UNK0
Date issued 18/07/2023
Strike 17.26 $
Maturity Unlimited
Parity 10 : 1
Emission price 0.82
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 0.83
Lowest since issue 0.1
Spread 0.02
Spread %18.18%

Company Profile

Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. The business is organized around 3 product families: - health products: for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - body care products: hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.); - other: notably oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.). Product marketing is assured through direct sales, distributors and the Internet.
Sector
-
More about the company

Ratings for Kenvue Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Kenvue Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
18.18 USD
Average target price
22.54 USD
Spread / Average Target
+23.97%
Consensus